In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

3D echocardiography improves the agreement between left ventricular and right ventricular stroke volumes in healthy individuals.

Session Poster session 5

Speaker Anna Pilalidou

Congress : EuroEcho 2019

  • Topic : imaging
  • Sub-topic : 3D Echocardiography
  • Session type : Poster Session
  • FP Number : P1559

Authors : AP Pilalidou (Thessaloniki,GR), VK Kantartzi (Thessaloniki,GR), CA Adamopoulos (Thessaloniki,GR), LZ Zitiridou (Thessaloniki,GR), MD Dimtsa (Thessaloniki,GR), SS Sotiriou (Thessaloniki,GR), AK Karakanas (Thessaloniki,GR), NS Stamatiadis (Thessaloniki,GR), VM Moschovidis (Thessaloniki,GR), NK Koutavas (Thessaloniki,GR), IZ Zaravalis (Thessaloniki,GR), MK Konstantinidou (Thessaloniki,GR), CG Gogos (Thessaloniki,GR), IS Styliadis (Thessaloniki,GR), VS Sachpekidis (Thessaloniki,GR)

AP Pilalidou1 , VK Kantartzi1 , CA Adamopoulos2 , LZ Zitiridou1 , MD Dimtsa1 , SS Sotiriou1 , AK Karakanas1 , NS Stamatiadis1 , VM Moschovidis1 , NK Koutavas1 , IZ Zaravalis1 , MK Konstantinidou1 , CG Gogos1 , IS Styliadis1 , VS Sachpekidis1 , 1Hospital Papageorgiou - Thessaloniki - Greece , 2Hippokration General Hospital of Thessloniki - Thessaloniki - Greece ,


Background/Introduction: Calculation of the LV and RV stroke volumes (SV) with the volumetric method can be useful for assessment of valvular regurgitant volumes and intracardiac shunt ratios. However, this method often yields significant differences between the estimated LV and RV SV even in healthy subjects.  We hypothesized that this discrepancy can be largely due to the assumption of LV and RV outflow tract circularity which forms the basis of 2D derived areas.
Purpose: To assess if the use of 3D transoesophageal (TOE) derived LVOT and RVOT areas can improve the agreement between LV and RV stroke volumes using the volumetric approach in healthy subjects with no valvular abnormality or intracardiac shunt.
Methods: We studied 20 patients (9 Males, age: 51±19 y) submitted to TOE for various reasons, who had normal cardiac anatomy and function and good quality 3D TOE LVOT and RVOT data.  Two dimensional TOE measurements of the LVOT and RVOT diameters were made in a zoomed mid oesophageal long axis and short axis view respectively; using these measurements 2D TOE LVOT and RVOT derived areas were calculated assuming circularity.  In a similar way, we calculated the 2D LVOT and RVOT areas using data from transthoracic echo (TTE) for each patient. Offline analysis of the 3D TOE data allowed direct planimetry of the LVOT and RVOT areas devoid of any geometric assumptions. Finally, calculation of the 2D TTE, 2D TOE and 3D TOE LV and RV stroke volumes were performed for each patient based on the acquired data. The difference between LV and RV stroke volume (which theoretically should be around zero) for each technique and for each patient was also calculated.
Results: The mean LV and RV SV for the whole cohort, did not differ significantly within each method: 2D-TTE. However, the mean absolute difference between LV and RV stoke volumes for each technique was significantly lower with the use of 3D TOE compared to both 2D TTE  and 2D TOE. Mean values and dispersion of absolute differences for each method are shown in Figure 1.
Conclusions: Compared to 2D, use of direct 3D TOE RVOT and LVOT planimetry yielded significantly less difference between RV and LV stroke volumes in healthy individuals. This finding can have potential clinical implications for more accurate assessment of valvular regurgitant volumes or intracardiac shunts.

Absolute mean defference between LV and RV 95%ΔΕ F(2.38) p-value
TTE 2D 18,65±11,72 (13,2-24,1) 8.63 0.001
TOE 2D 13,45±12,44 (7,6-19.3) 8.63 0.001
TOE 3D 6,45±3,62 (4,8-8,1) 8.63 0.001

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are